Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsRanbaxylaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Two pharma stocks that can improve health of your portfolio

      Ranbaxy and Cipla were at 52 week highs on Monday. Kour expects Cipla to perform well going ahead. She is bullish on this stock; however, she is cautious on Ranbaxy.

    • Buy Ranbaxy Laboratories, says PN Vijay

      Buy Ranbaxy Laboratories, says PN Vijay, Portfolio Manager.

    • Looking for bottom fishing bets? PN Vijay suggests 2 stocks

      Portfolio manager PN Vijay says if one is going in for bottom fishing, Bharat Heavy Electricals and Ranbaxy are attractive buys.

    • Buy Ranbaxy Laboratories, says Sukhani

      Buy Ranbaxy Laboratories, says Sudarshan Sukhani of s2analytics.com. Yesterday it had a big move. We don‘t know if there will be follow-up or if there will be consolidation. If the stock decides to move up after the first half an hour it‘s an intraday buy again today.

    • Super Six stocks you can bet on September 04

      On CNBC-TV18's show Super Six, market gurus Vishal Kshatriya of Edelweiss, Arunesh Madan of Augment Investment and Rakesh Gandhi of LKP, place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • 6 trading bets that can fetch you handsome returns

      On CNBC-TV18's show Super Six, market gurus Manas Jaiswal of manasjaiswal.com, Rajesh Jain of Religare Securities and Shardul Kulkarni of Angel Broking, place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • Hold Sun Pharma, Ranbaxy Labs: PN Vijay

      PN Vijay, Portfolio Manager, www.askpnvijay.com is of the view that one can hold big pharma stocks like Sun Pharma, Ranbaxy Labs for some more time but not to buy these stocks, which have run up a lot.

    • Buy NHPC at current level: Panda

      Jitendra Panda, Future Capital is positive on power sector and has recommended one can buy NHPC even at current level.

    • Buy Ipca Labs, Ranbaxy Labs: Pankaj Jain

      In CNBC-TV18's popular show Bull's Eye, Pankaj Jain, Sunteck Wealthmax shares trading strategy of the day.

    • Bull's eye: Buy Opto Circuits, Ceat; short NCC, R Power

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Ranbaxy Labs has target of Rs 570: Bothra

      Ranbaxy Laboratories is looking good around the level of Rs 555. One can go long on the stock with a stop loss of Rs 545, for a target of Rs 570, says Kunal Bothra, Sr Technical Analyst at LKP.

    • Hold Ranbaxy Labs with stop loss of Rs 540: Anu Jain

      Anu Jain of IIFL Private Wealth Management advice traders to hold Ranbaxy Labs with stop loss of Rs 540.

    • Ranbaxy Labs good long term bet, says Dilip Bhat

      One can take long term call on Ranbaxy Labs as it has potential to double even from the current levels, says Dilip Bhat, Joint MD, Prabhudas Lilladher.

    • Buy Ranbaxy, sell Bharti Airtel: Mehta

      Dipesh Mehta, Nirmal Bang Securities is of the view that one can buy Ranbaxy Laboratories on every dip while sell Bharti Airtel on every rise.

    • Drug makers in India to sustain 'premium' valuations: HSBC

      HSBC raises target prices for some Indian drug makers saying "robust" earnings will help sustain the "premium" valuations in the sector.

    • Ranbaxy has target of Rs 582, says Mohindar

      Ranbaxy Laboratories is a safe havens in pharma space, one can hold the stock for a target of Rs 582, says Rahul Mohindar of viratechindia.com.

    • Buy Ranbaxy Labs, Dr Reddys Labs, BoB: Merani

      In CNBC-TV18's popular show Bull's Eye, Nooresh Merani, AMSEC Research shares trading strategy of the day.

    • Ranbaxy Laboratories looks strong: Hemant Thukral

      Ranbaxy Laboratories is looking strong, says Hemant Thukral, Aditya Birla Money.

    • Jet Airways has target of Rs 490-500: Sukhani

      Jet Airways has very attractive bullish charts. The eventual target for this move is Rs 490-500. I would be long at every dip, says Sudarshan Sukhani of s2analytics.com.

    • Bull's eye: Buy Ranbaxy, Hexaware, MTNL, Fame India

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Ranbaxy Labs, Coal India, HDFC look good: Bhat

      Ranbaxy Labs, Coal India and HDFC are looking good at current level, says Dilip Bhat, Joint MD, Prabhudas Lilladher.

    • Short Educomp Solutions: Sukhani

      Short Educomp Solutions, says Sudarshan Sukhani, s2analytics.com.

    • Sell Ranbaxy Laboratories, says Anu Jain

      Sell Ranbaxy Laboratories, says Anu Jain, Senior VP, IIFL Private Wealth Management.

    • Short Bharti Airtel, says Sudarshan Sukhani

      Short Bharti Airtel, says Sudarshan Sukhani of s2analytics.com.

    • Buy Hindalco, GMDC, Colgate: Merani

      In CNBC-TV18's popular show Bull's Eye, Nooresh Merani, AMSEC Research shares trading strategy of the day.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347